Pure Global AI
NCT06376097Recruiting

Lung Cancer Screening Program Using Low-dose Tomography and Metabolomic Evaluation in a Public Service.

Implementation of a Lung Cancer Screening Program in a Public Service, Using Low-dose Tomography and Metabolomics Evaluation
AstraZenecaClinicalTrials.gov
Verified
Study focus
Disease/Condition
Lung Cancer
Study type
Observational
Sponsor & location
Primary sponsor
AstraZeneca
Location
Botucatu, Brazil
Timeline & enrollment
Phase
N/A
Start date
Apr 19, 2023
End date
Jan 30, 2025
Enrollment
1000 participants
Primary outcome

Absolute number and frequency of false-negative lung nodules .

Summary

Observational study that aims to evaluate the implementation of a lung cancer screening
 program in a smoker population included in a public heath service.

ICD-10 classifications
Carcinoma in situ: Bronchus and lungSecondary malignant neoplasm of lungMalignant neoplasm of bronchus and lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm: Overlapping lesion of bronchus and lung
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06376097
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06376097 through Pure Global AI's free database. This phase not specified trial is sponsored by AstraZeneca and is currently Recruiting. The study focuses on Lung Cancer. Target enrollment is 1000 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.